NEULANDLAB - Neuland Laboratories Limited. Share Price

Management's outlook for Neuland Laboratories is cautiously optimistic, as they highlighted strong growth for FY26 compared to FY24, with total income reaching INR 2,053.1 crores, a 37.1% increase from INR 1,497.3 crores. The company noted that while FY25 was a period of slight degrowth, they anticipated strong growth for FY26, which was achieved and slightly exceeded expectations due to favorable exchange rates.

Key financial metrics for Q4FY26 included:

• Total income: INR 788.7 crores (up 134.9% YoY)
• Gross margin: 62.1% (compared to 56.3% in Q4FY25)
• EBITDA: INR 319.4 crores (40.5% margin)
• Profit after tax: INR 212.5 crores (compared to INR 27.7 crores in Q4FY25)
• EPS: INR 165.6 per share

For FY26, EBITDA was INR 603.4 crores with a margin of 29.4%, and profit after tax was INR 363.1 crores with an EPS of INR 283.01.

Management indicated that the inherent lumpiness of income would continue, influenced by the dynamics of their commercial projects, and they sought to emphasize medium- to long-term visibility anchored by commercial and near-commercial molecules.

Major forward-looking points included:

• Investment in large-scale peptide manufacturing facilities, which is expected to diversify their product offerings beyond peptide fragments to peptide APIs.
• Upgrades to their R&D capabilities to support complex projects and enhance their engagement with clients.
• A steady focus on customer satisfaction and execution discipline to ensure sustainable profitability.

Management maintains a forward-looking growth outlook, with growth over the next 2"“3 years identified as promising, dependent on the existing pipeline, while remaining responsive to uncertainties in demand, regulatory timelines, and supply chain issues. They emphasized a commitment to building operational resilience and improving cash flows through disciplined capital expenditure.

1. Question: "What is driving the performance of our CDMO business for the quarter? Is it existing commercial projects, new products, or does it relate to order volumes from the last quarter?"

Answer: "The growth is primarily driven by our existing pipeline, particularly through ramp-ups of previously commercialized products. While we did have one new commercialization this year, most of the growth comes from these established products. The currency depreciation helped our Q4 performance, influencing shipping volumes, but the underlying growth is rooted in the strength of our existing offerings."

2. Question: "What value add are we providing as a CDMO for the peptide contract recently announced?"

Answer: "The contract involves early-stage programs, which means we aren't expecting immediate revenue. We're developing several peptide programs for various therapeutic indications, but none are close to commercialization just yet. This pipeline potentially offers significant value, but we will need years for many projects to yield tangible benefits. It's a long-term play."

3. Question: "As we grow our peptide business, what are our key selling points to attract clients?"

Answer: "Our key selling point lies in our long history in peptide development, where we have built expertise in process chemistry. This allows us to create a strong foundation in manufacturing infrastructure and R&D, making us an attractive partner for clients looking for reliable CDMO services across complex programs and projects."

4. Question: "What do you believe is Neuland's biggest capability gap to participate in the emerging hybrid modalities like ADCs?"

Answer: "While we acknowledge that advanced modalities like ADCs and fermentation technologies are gaining traction, peptides still offer significant value. Our strategy focuses on long-term growth through our current expertise in complex small molecules and peptides. We see potential in leveraging our capabilities into adjacent areas rather than diverting resources into new, unfamiliar modalities at this time."

5. Question: "Regarding the transaction affecting Esperion, how do you see the future of bempedoic acid and supply agreements with CDMO businesses?"

Answer: "Such M&A in biotech is common and generally does not disrupt supply agreements, as these include continuity clauses. We prioritize secure supply relationships with our clients to ensure patient access to medicines. Therefore, we don't foresee immediate risks from these changes, and our outlook remains stable as we continue to engage with our CDMO customers."

6. Question: "Given the realities of biotech funding, how is this trend impacting your business and client inquiries?"

Answer: "The decline in funding primarily affects early-stage projects, while our focus remains on molecules nearing commercialization. We have not directly felt the impact as we continue to engage clients developing promising therapies. Our strategy targets those molecules entering phase one onwards, allowing us to remain insulated from short-term funding fluctuations."

7. Question: "Are we on track for the peptide facility to become operational in July? Will we have firm contracts in place?"

Answer: "Yes, the facility will be operational as scheduled in July. While we don't have firm contracts yet given the early-stage focus of the projects, we do have visibility and anticipate ramping up projects quickly to feed into this new facility. We're excited about the potential once it's fully operational."

8. Question: "Could you clarify the nature of volatility in your business and your outlook for future quarters?"

Answer: "Volatility is inherent in our business, often driven by high-value new molecules that can lead to uneven revenue. This is expected and part of our growth story, as newer molecules bring both opportunity and unpredictability. While some quarters may show less performance, assessing over a longer timeframe gives a clearer growth picture."

9. Question: "How should investors interpret current and future margins, especially as you talk about FY27 or FY28?"

Answer: "We maintain an 18% to 20% CAGR growth target over the long term, though the trajectory may not be linear. Given our conservative budgeting habits factored in for exchange rates and materials costs, expecting margins to improve may be realistic based on historical performance rather than Q4 alone. Overall, we anticipate underlying business growth will support our profitability goals."

10. Question: "What are your plans for AI integration into manufacturing processes to enhance operations?"

Answer: "Currently, we're exploring AI applications in repetitive tasks, especially in R&D and manufacturing data analysis to identify operational issues. We're at the initial stage of these explorations but are committed to integrating effective AI solutions into our processes as we move forward."